- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01810003
Impact of EPA and DHA Supplementation on Plasma Biomarkers of Inflammation (n3) (n3)
Impact of EPA and DHA Supplementation on Plasma Biomarkers of Inflammation in Men and Women With Metabolic Syndrome
Subclinical inflammation is now indisputably recognized as a key etiological factor in the development of atherosclerosis and subsequent cardiovascular disease. Obesity and related dysmetabolic states including metabolic syndrome (MetS) are highly prevalent causes of subclinical inflammation. Obesity and MetS are both diet and lifestyle-related and there is a growing body of literature suggesting that specific nutrients, such as long chain omega-3 polyunsaturated fatty acids (LCn-3PUFA), may attenuate the pro-inflammatory state associated with these conditions. However, careful review of existing literature on this topic reveals important gaps in knowledge, the purported anti-inflammatory effects of LCn-3PUFA even being questioned by many. Significant confounding attributable to study design, sample size and biomarker selection may be responsible in part for inconsistencies in the literature on LCn-3PUFA and inflammation. We also found that evidence available to date (for and against) is based primarily on secondary analyses, as most of the studies published were not primarily designed to investigate inflammation as a primary outcome. It remains unclear whether the different LCn-3PUFA, primarily docosahexaenoic acid (DHA, 22:6n-3) and eicosapentaenoic acid (EPA, 20:5n-3), have similar effects on pro-inflammatory processes as almost all studies were undertaken using a mix of LCn-3PUFA. Whether efficacy of EPA and DHA is influenced by sex/gender is also unknown. Finally, a better understanding of the systemic and tissue-specific mechanisms underlying the anticipated anti-inflammatory effects of different LCn-3PUFA in MetS would also be of great value. Addressing these gaps has important public health implications, considering that LCn-3PUFA supplements are broadly and indiscriminately recommended for the prevention of cardiovascular disease.
The overarching objective of the proposed research is to compare the anti-inflammatory effects of EPA and DHA in men and women with MetS.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Quebec, Canada, G1V 0A6
- Institute of Nutrition and Functional Foods (INAF), Laval University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women aged between 18 and 70 years with abdominal obesity as defined by the International Diabetes Federation criteria and a measure of plasma CRP >1 mg/L
- Stable body weight for at least 3 months prior to randomization.
- Pre-menopausal women with regular menstrual cycle (25-35 days)
Exclusion Criteria:
- Plasma CRP > 10 mg/L at screening
- Extreme dyslipidemias such as familial hypercholesterolemia
- Previous history of cardiovascular disease (coronary heart disease, cerebrovascular disease or peripheral arterial disease)
- Subjects taking medications known to affect inflammation (e.g. steroids, binging alcohol)
- Subjects taking LCn-3PUFA supplements within 2 months of study onset.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: High DHA
High DHA supplementation (3g/day)
|
10 week supplementation period
|
Experimental: High EPA
EPA supplementation (3g/day)
|
10 week supplementation period
|
Placebo Comparator: Placebo
Placebo (3g corn oil/day)
|
10 week supplementation period
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in plasma biomarkers of inflammation (CRP, Interleukin (IL)-6, IL-18 and Tumor necrosis factor-α)
Time Frame: At the beginning and the end of each 10-week period
|
Change between treatments based on post-treatment values, adjusting for treatment-specific baseline values
|
At the beginning and the end of each 10-week period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in lipid concentrations (LDL-C, HDL-C, TG)
Time Frame: At the beginning and the end of each 10-week period
|
Change between treatments based on post-treatment values, adjusting for treatment-specific baseline values
|
At the beginning and the end of each 10-week period
|
Change in blood pressure
Time Frame: At the beginning and the end of each 10-week period
|
Change between treatments based on post-treatment values, adjusting for treatment-specific baseline values
|
At the beginning and the end of each 10-week period
|
Change in endogenous production and clearance rate of CRP (in a subsample of the entire study population)
Time Frame: At the end of the three 10-week periods
|
Change between treatments based on post-treatment values
|
At the end of the three 10-week periods
|
Change in expression of inflammation genes in peripheral blood cells (in a subsample of the entire study population)
Time Frame: At the end of the three 10-week periods
|
Change between treatments based on post-treatment values
|
At the end of the three 10-week periods
|
Change in anthropometric measures (waist and hip circumference)
Time Frame: At the beginning and the end of each 10-week period
|
Change between treatments based on post-treatment values, adjusting for treatment-specific baseline values
|
At the beginning and the end of each 10-week period
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Vallee Marcotte B, Allaire J, Guenard F, de Toro-Martin J, Couture P, Lamarche B, Vohl MC. Genetic risk prediction of the plasma triglyceride response to independent supplementations with eicosapentaenoic and docosahexaenoic acids: the ComparED Study. Genes Nutr. 2020 Jun 15;15(1):10. doi: 10.1186/s12263-020-00669-x.
- Allaire J, Vors C, Tremblay AJ, Marin J, Charest A, Tchernof A, Couture P, Lamarche B. High-Dose DHA Has More Profound Effects on LDL-Related Features Than High-Dose EPA: The ComparED Study. J Clin Endocrinol Metab. 2018 Aug 1;103(8):2909-2917. doi: 10.1210/jc.2017-02745.
- Vors C, Allaire J, Marin J, Lepine MC, Charest A, Tchernof A, Couture P, Lamarche B. Inflammatory gene expression in whole blood cells after EPA vs. DHA supplementation: Results from the ComparED study. Atherosclerosis. 2017 Feb;257:116-122. doi: 10.1016/j.atherosclerosis.2017.01.025. Epub 2017 Jan 20.
- Allaire J, Couture P, Leclerc M, Charest A, Marin J, Lepine MC, Talbot D, Tchernof A, Lamarche B. A randomized, crossover, head-to-head comparison of eicosapentaenoic acid and docosahexaenoic acid supplementation to reduce inflammation markers in men and women: the Comparing EPA to DHA (ComparED) Study. Am J Clin Nutr. 2016 Aug;104(2):280-7. doi: 10.3945/ajcn.116.131896. Epub 2016 Jun 8.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- INAF-2012-143
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Disease, Inflammation
-
Penn State UniversityUnited States Department of Agriculture (USDA)CompletedInflammation | Cardiovascular DiseaseUnited States
-
New York State Psychiatric InstituteFeinstein Institute for Medical ResearchCompleted
-
Laval UniversityDairy Farmers of CanadaCompletedCardiovascular DiseaseCanada
-
Skane University HospitalCompletedInflammation | Cardiovascular Disease | Diet
-
Penn State UniversityMcCormick Science InstituteCompletedInflammation | Cardiovascular DiseaseUnited States
-
Icahn School of Medicine at Mount SinaiMassachusetts General Hospital; National Heart, Lung, and Blood Institute (NHLBI) and other collaboratorsCompletedAtherosclerotic Cardiovascular Disease | Vascular InflammationUnited States, Canada
-
Priscilla Hsue, MDUniversity of California, Los Angeles; University of UtahWithdrawnHIV Infection | Inflammation | Cardiovascular DiseaseUnited States
-
Guy's and St Thomas' NHS Foundation TrustUnknownCardiovascular Diseases | Systemic Inflammation | Metabolic Disease | Immune FunctionUnited Kingdom
-
University Hospital, LinkoepingCompletedInflammation | Exercise | Risk Factors Cardiovascular Disease | Sedentary LifeSweden
-
Priscilla Hsue, MDMassachusetts General HospitalCompletedCardiovascular Disease | HIVUnited States
Clinical Trials on High DHA
-
Mead Johnson NutritionChinese Academy of Sciences; International Peace Maternity and Child Health...WithdrawnAtopic DermatitisChina
-
Mead Johnson NutritionUniversity of Kansas; John Colombo, PhD, The University of KansasTerminatedMeasurement of Docosahexaenoic Acid Levels in Pre-school ChildrenUnited States
-
CHU de Quebec-Universite LavalCanadian Institutes of Health Research (CIHR); McGill University Health Centre... and other collaboratorsActive, not recruitingChild Development | Bronchopulmonary Dysplasia | Neonatal and Perinatal ConditionsCanada
-
University of ManitobaCanadian Institutes of Health Research (CIHR); Agriculture and Agri-Food CanadaCompleted
-
Mead Johnson NutritionWithdrawnCow's Milk Allergy | Intolerance to Extensively Hydrolyzed Formulas | Intolerance to Breast MilkUnited Kingdom
-
University of GuelphOntario Ministry of Agriculture, Food and Rural AffairsCompletedCardiovascular Disease
-
University of Kansas Medical CenterActive, not recruitingPregnancy; Nutritional DiseasesUnited States
-
University of New MexicoNational Center for Research Resources (NCRR)TerminatedPregnancy | Randomized Clinical Trial | Docosahexaenoic AcidUnited States
-
Wei JiangNational Institute of Mental Health (NIMH)Completed
-
University of Alabama at BirminghamMead Johnson NutritionNot yet recruitingPremature | Infant Malnutrition | Nutrition Disorder, Infant | Light-For-Dates With Signs of Fetal MalnutritionUnited States